GeneXpert CARBA-R assay for molecular characterization of carbapenem-resistance in Gram-negative bacteria in a tertiary care university hospital in Cairo-Egypt
Infection · 2026-10 · 54 (5) · 2389-2395
DOI: 10.1007/s15010-026-02850-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection, online erschienen am 03.06.2026. Verfasst von Heba Shawky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Chemical Microbiology Department, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: beta-Lactamases, Bacterial Proteins, Carbapenems, Gram-Negative Bacteria. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Pfizer pharmaceutical company in Egypt provided us with the GeneXpert kits used in this study.
Abstract (Originalsprache)
BACKGROUND: Carbapenem-resistant Enterobacterales are prevalent and increasingly reported in Egyptian hospitals. Carbapenemase production is the main mechanism of carbapenem resistance that carries the risk of dissemination among different bacterial species. PURPOSE: the study aimed to detect the distribution of carbapenemase genes among Enterobacterales and Pseudomonas species isolated from clinical samples in a tertiary care university hospital in Cairo, Egypt. METHODS: GeneXpert real time multiplex PCR was used for detection of carbapenemase genes in carbapenem-resistant isolates from patients admitted to Cairo University hospitals during the period from September 2021 to July 2023. Carbapenem-resistant isolates were identified by conventional antimicrobial susceptibility testing using the disc diffusion method. E. coli ATCC® 25922™ and Pseudomonas aeruginosa ATCC® 27853™ were used as quality control strains for disc diffusion. The isolates were tested for each of the following genes, blaKPC, blaNDM, blaOXA, blaVIM and blaIMP. RESULTS: A total of 330 carbapenem-resistant isolates were identified. A single carbapenemase gene was detected in 106 (32.1%) of isolates, 211 (63.9%) had two genes compared to three genes in six (1.8%) of isolates. The most common resistance gene was blaNDM (90.3%) followed by blaOXA (68.5%). CONCLUSION: The detection of carbapenemase genes using the GeneXpert Carba-R assay represents a significant advancement in combating antimicrobial resistance. This assay is easy and rapid; offering results within approximately 50 min; thus, represents significant added value to traditional culture methods, which require 48 h or more. Despite the advantages of GeneXpert, the assay has some limitations, as it targets only the five most common carbapenemase gene families, and may miss less common genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Chemical Microbiology Department, Cairo University, Cairo, Egypt.
- Clinical and Chemical Microbiology Department, Cairo University, Cairo, Egypt. eimanmousa@yahoo.com.
- Department of Anesthesiology, Cairo University Hospitals, Cairo, Egypt.
Förderung
- Pfizer pharmaceutical company in Egypt provided us with the GeneXpert kits used in this study
Zitieren
APA
Shawky, H., El Banna, A. M. S., AbdulRahman, E. M., Mokhtar, A., & Balah, M. M. (2026). GeneXpert CARBA-R assay for molecular characterization of carbapenem-resistance in Gram-negative bacteria in a tertiary care university hospital in Cairo-Egypt. Infection, 54(5), 2389-2395. https://doi.org/10.1007/s15010-026-02850-7
Vancouver
Shawky H, El Banna AMS, AbdulRahman EM, Mokhtar A, Balah MM. GeneXpert CARBA-R assay for molecular characterization of carbapenem-resistance in Gram-negative bacteria in a tertiary care university hospital in Cairo-Egypt. Infection. 2026;54(5):2389-2395. doi:10.1007/s15010-026-02850-7
BibTeX
@article{Shawky2026,
author = {Shawky, Heba and El Banna, Afaf Mohamed Samy and AbdulRahman, Eiman Mohammed and Mokhtar, Ahmed and Balah, Mariam Mahmoud},
title = {GeneXpert CARBA-R assay for molecular characterization of carbapenem-resistance in Gram-negative bacteria in a tertiary care university hospital in Cairo-Egypt},
journal = {Infection},
year = {2026},
volume = {54},
number = {5},
pages = {2389--2395},
doi = {10.1007/s15010-026-02850-7}
}
EUVIMED